Perfusion of donor endothelial progenitor cell perfusion prolongs the survival of rat cardiac allograft

Li-min XIA,Yong-xin SUN,Qiang ZHAO

DOI: https://doi.org/10.3969/j.issn.1672-8467.2008.06.017

2008-01-01

Abstract:Objective To study the effect of endotherial progenitor cell (EPC) perfusion on survival time of cardiac allograft and acute rejection in heart transplantation. Methods The mononuclear cells were isolated from bone marrow of Sprague Dawley (SD) rats by density gradient centrifugation and cultured for 48 hours. Then the wall attached cells were cultured in the selective culture medium (with the supplement of VEGF, bFGF, IFG-1 and EGF) for 2 weeks. The cells were stained with Dil-ac-LDL and FITC-UEA-1 for identification. Twenty pairs of Wistar rats and SD rats were randomizely divided into four groups (5 pairs in each group). The animal transplantation model was used. Group I was set up as the control group. In Group II, the rats were fed with CsA after transplantation for 7 days. In Group III, the donor heart were perfused with 1 × 10 6 EPCs before implantation. In Group IV, the donor hearts were perfused with 1 × 106 EPCs before implantation and the rats were fed with CsA after transplantation for 7 days. Results The attached cells stretched, differentiated, and exhibited the colonal morphology after inducing culture for 3 to 5 days. The cells proliferated faster after 7 to 10 days incubation when cord-like structure was observed. After 2-week induction, most of the cells exhibited multi-angular morphology. More than 70 % cells were stained positively with Dil-ac-LDL and FITC-UEA-1 (double positive fluorescence). The average donor heart survival time was (6. 2 ± 0. 8)days in Group I, (11.6 ± 1. 1) days in Group II, (9. 4 ± 1. 1) days in Group III and (18. 8 ± 1. 6) days in Group IV. The survival times in Group II, III and IV were prolonged significantly than that of the Group I (P<0. 01). The survival time in Group IV was the longest among these four groups (P<0. 01). Conclusions EPC perfusion with CsA administration prolongs the survival time of the allograft heart.